Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by Geri Gentry on May 20th, 2026

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $57.75.

IMCR has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Tuesday, April 21st. Jefferies Financial Group downgraded Immunocore from a “buy” rating to a “hold” rating and lowered their price target for the stock from $48.00 to $33.00 in a report on Monday, March 16th. Zacks Research upgraded Immunocore from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, May 7th. Mizuho set a $38.00 price objective on Immunocore in a report on Thursday, February 19th. Finally, Wall Street Zen upgraded Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, May 9th.

Get Our Latest Stock Analysis on IMCR

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Leonteq Securities AG bought a new position in shares of Immunocore during the fourth quarter worth about $30,000. Harbour Investments Inc. raised its stake in Immunocore by 60.2% in the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in shares of Immunocore in the fourth quarter valued at approximately $47,000. Arax Advisory Partners lifted its position in shares of Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after buying an additional 1,042 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after buying an additional 572 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Trading Up 2.0%

NASDAQ IMCR opened at $28.93 on Wednesday. The stock has a 50-day simple moving average of $30.29 and a 200 day simple moving average of $33.08. The company has a market capitalization of $1.47 billion, a PE ratio of -52.60 and a beta of 0.74. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. Immunocore has a 12 month low of $27.56 and a 12 month high of $40.71.

Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The business had revenue of $106.68 million during the quarter, compared to the consensus estimate of $145.20 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. Research analysts forecast that Immunocore will post -0.16 EPS for the current year.

Immunocore Company Profile

(Get Free Report)

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.